Show simple item record

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

dc.contributor.authorZinzani, PL
dc.contributor.authorSalles, G
dc.contributor.authorMoskowitz, AJ
dc.contributor.authorSantoro, A
dc.contributor.authorMehta, A
dc.contributor.authorBarr, PM
dc.contributor.authorMehta-Shah, N
dc.contributor.authorCollins, GP
dc.contributor.authorAnsell, SM
dc.contributor.authorBrody, JD
dc.contributor.authorDomingo-Domenech, E
dc.contributor.authorJohnson, NA
dc.contributor.authorCunningham, D
dc.contributor.authorFerrari, S
dc.contributor.authorLisano, J
dc.contributor.authorKrajewski, J
dc.contributor.authorWen, R
dc.contributor.authorAkyol, A
dc.contributor.authorCrowe, R
dc.contributor.authorSavage, KJ
dc.coverage.spatialUnited States
dc.date.accessioned2024-08-16T10:00:13Z
dc.date.available2024-08-16T10:00:13Z
dc.date.issued2024-05-28
dc.identifier515499
dc.identifier.citationBlood Advances, 2024, 8 (10), pp. 2400 - 2404en_US
dc.identifier.issn2473-9529
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6361
dc.identifier.eissn2473-9537
dc.identifier.eissn2473-9537
dc.identifier.doi10.1182/bloodadvances.2023011030
dc.identifier.doi10.1182/bloodadvances.2023011030
dc.formatPrint
dc.format.extent2400 - 2404
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofBlood Advances
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectHumans
dc.subjectBrentuximab Vedotin
dc.subjectLymphoma, T-Cell, Peripheral
dc.subjectNivolumab
dc.subjectLymphoma, T-Cell, Cutaneous
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAged
dc.subjectNeoplasm Recurrence, Local
dc.subjectAdult
dc.subjectSkin Neoplasms
dc.titleNivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-02-28
dc.date.updated2024-08-16T09:59:26Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1182/bloodadvances.2023011030en_US
rioxxterms.licenseref.startdate2024-05-28
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38531062
pubs.issue10
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-groupICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1182/bloodadvances.2023011030
pubs.volume8
icr.researchteamMedicine (RMH)en_US
dc.contributor.icrauthorCunningham, David
icr.provenanceDeposited by Mr Arek Surman on 2024-08-16. Deposit type is initial. No. of files: 1. Files: Nivolumab plus brentuximab vedotin for relapsedrefractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.pdf


Files in this item

Thumbnail
Name:
Nivolumab plus brentuximab vedotin ...
Size:
397.1Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/